Clinuvel Pharmaceuticals Limited
CLVLY · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 1.28 | 0.61 | -2.20 |
| FCF Yield | 7.89% | 4.28% | 4.04% | 5.37% |
| EV / EBITDA | 5.14 | 9.80 | 20.75 | 20.95 |
| Quality | ||||
| ROIC | 13.10% | 16.36% | 16.22% | 15.32% |
| Gross Margin | 83.29% | 91.23% | 64.59% | 70.93% |
| Cash Conversion Ratio | – | – | 1.21 | 1.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.65% | 10.29% | 17.75% | 26.37% |
| Free Cash Flow Growth | 29.61% | -12.28% | -9.01% | 114.25% |
| Safety | ||||
| Net Debt / EBITDA | -3.91 | -3.25 | -0.55 | -0.77 |
| Interest Coverage | 10.25 | 10.78 | 12.81 | 14.55 |
| Efficiency | ||||
| Inventory Turnover | 1.80 | 0.73 | 2.91 | 10.43 |
| Cash Conversion Cycle | 249.62 | 499.48 | 184.75 | 120.03 |